All In Biotech

Drug Trial Radar · NCT05886088

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 597 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

597

Planned (sponsor's estimate)

Start

Feb 2024

Primary completion

May 2026

Study completion Jan 2027

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • LID104Drug

    Experimental

  • DapagliflozinDrug

    Active comparator

  • LinagliptinDrug

    Active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glycated hemoglobin (HbA1c)Time frame: 120 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site

    Hortolândia, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.